

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM D

Notice of Exempt Offering of Securities

OMB APPROVAL	
OMB Number:	3235-0076
Estimated average burden hours per response:	4.00

1. Issuer's Identity

CIK (Filer ID Number) 0001372514	Previous Names X None	Entity Type X Corporation Limited Partnership Limited Liability Company General Partnership Business Trust Other (Specify)
Name of Issuer EYEGATE PHARMACEUTICALS INC		
Jurisdiction of Incorporation/Organization DELAWARE		
Year of Incorporation/Organization X Over Five Years Ago Within Last Five Years (Specify Year) Yet to Be Formed		

2. Principal Place of Business and Contact Information

Name of Issuer EYEGATE PHARMACEUTICALS INC			
Street Address 1 271 WAVERLEY OAKS ROAD, SUITE 108		Street Address 2	
City WALTHAM	State/Province/Country MASSACHUSETTS	ZIP/PostalCode 02452	Phone Number of Issuer 781-788-9043

3. Related Persons

Last Name Strem	First Name Brian	Middle Name
Street Address 1 271 Waverley Oaks Road, Suite 108	Street Address 2	
City Waltham	State/Province/Country MASSACHUSETTS	ZIP/PostalCode 02452
Relationship: X Executive Officer X Director Promoter		

Clarification of Response (if Necessary):

President and Chief Executive Officer

Last Name Romano	First Name Sarah	Middle Name
Street Address 1 271 Waverley Oaks Road, Suite 108	Street Address 2	
City Waltham	State/Province/Country MASSACHUSETTS	ZIP/PostalCode 02452
Relationship: X Executive Officer Director Promoter		

Clarification of Response (if Necessary):

Chief Financial Officer

Last Name	First Name	Middle Name
From	Stephen	
Street Address 1	Street Address 2	
271 Waverley Oaks Road, Suite 108		
City	State/Province/Country	ZIP/PostalCode
Waltham	MASSACHUSETTS	02452
Relationship: X Executive Officer X Director Promoter		

Clarification of Response (if Necessary):

Executive Chairman

Last Name	First Name	Middle Name
Chaney	Paul	
Street Address 1	Street Address 2	
271 Waverley Oaks Road, Suite 108		
City	State/Province/Country	ZIP/PostalCode
Waltham	MASSACHUSETTS	02452
Relationship: Executive Officer X Director Promoter		

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Shapiro	Aron	
Street Address 1	Street Address 2	
271 Waverley Oaks Road, Suite 108		
City	State/Province/Country	ZIP/PostalCode
Waltham	MASSACHUSETTS	02452
Relationship: Executive Officer X Director Promoter		

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Gayron	Kenneth	
Street Address 1	Street Address 2	
271 Waverley Oaks Road, Suite 108		
City	State/Province/Country	ZIP/PostalCode
Waltham	MASSACHUSETTS	02452
Relationship: Executive Officer X Director Promoter		

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Tyle	Praveen	
Street Address 1	Street Address 2	
271 Waverley Oaks Road, Suite 108		
City	State/Province/Country	ZIP/PostalCode
Waltham	MASSACHUSETTS	02452
Relationship: Executive Officer X Director Promoter		

Clarification of Response (if Necessary):

4. Industry Group

Agriculture
 Banking & Financial Services
 Commercial Banking
 Insurance
 Investing
 Investment Banking
 Pooled Investment Fund
 Is the issuer registered as an investment company under the Investment Company Act of 1940?

Yes No

Other Banking & Financial Services
 Business Services
 Energy
 Coal Mining
 Electric Utilities
 Energy Conservation
 Environmental Services
 Oil & Gas
 Other Energy

Health Care
 Biotechnology
 Health Insurance
 Hospitals & Physicians
 X Pharmaceuticals
 Other Health Care
 Manufacturing
 Real Estate
 Commercial
 Construction
 REITS & Finance
 Residential
 Other Real Estate

Retailing
 Restaurants
 Technology
 Computers
 Telecommunications
 Other Technology
 Travel
 Airlines & Airports
 Lodging & Conventions
 Tourism & Travel Services
 Other Travel
 Other

5. Issuer Size

Revenue Range	OR	Aggregate Net Asset Value Range
No Revenues		No Aggregate Net Asset Value
\$1 - \$1,000,000		\$1 - \$5,000,000
\$1,000,001 - \$5,000,000		\$5,000,001 - \$25,000,000
\$5,000,001 - \$25,000,000		\$25,000,001 - \$50,000,000
\$25,000,001 - \$100,000,000		\$50,000,001 - \$100,000,000
Over \$100,000,000		Over \$100,000,000
X Decline to Disclose		Decline to Disclose
Not Applicable		Not Applicable

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

	Investment Company Act Section 3(c)	
Rule 504(b)(1) (not (i), (ii) or (iii))	Section 3(c)(1)	Section 3(c)(9)
Rule 504 (b)(1)(i)	Section 3(c)(2)	Section 3(c)(10)
Rule 504 (b)(1)(ii)	Section 3(c)(3)	Section 3(c)(11)
Rule 504 (b)(1)(iii)	Section 3(c)(4)	Section 3(c)(12)
X Rule 506(b)	Section 3(c)(5)	Section 3(c)(13)
Rule 506(c)	Section 3(c)(6)	Section 3(c)(14)
Securities Act Section 4(a)(5)	Section 3(c)(7)	

7. Type of Filing

X New Notice Date of First Sale 2021-08-09 First Sale Yet to Occur
 Amendment

8. Duration of Offering

Does the Issuer intend this offering to last more than one year? Yes No

9. Type(s) of Securities Offered (select all that apply)

- | | |
|---------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------|
| <input type="checkbox"/> Equity | <input type="checkbox"/> Pooled Investment Fund Interests |
| <input type="checkbox"/> Debt | <input type="checkbox"/> Tenant-in-Common Securities |
| <input checked="" type="checkbox"/> Option, Warrant or Other Right to Acquire Another Security | <input type="checkbox"/> Mineral Property Securities |
| <input checked="" type="checkbox"/> Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security | <input type="checkbox"/> Other (describe) |

10. Business Combination Transaction

Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? Yes No

Clarification of Response (if Necessary):

11. Minimum Investment

Minimum investment accepted from any outside investor \$0 USD

12. Sales Compensation

Recipient	Recipient CRD Number	None
H.C. Wainwright & Co., LLC	375	
(Associated) Broker or Dealer <input checked="" type="checkbox"/> None	(Associated) Broker or Dealer CRD Number	<input checked="" type="checkbox"/> None
None	None	

Street Address 1

Street Address 2

430 PARK AVENUE

City	State/Province/Country	ZIP/Postal Code
NEW YORK	NEW YORK	10022

State(s) of Solicitation (select all that apply)
 Check "All States" or check individual States

All States Foreign/non-US

- FLORIDA
- ILLINOIS
- NEVADA
- NEW JERSEY
- NEW YORK
- TEXAS

13. Offering and Sales Amounts

Total Offering Amount \$10,750,013 USD or Indefinite
 Total Amount Sold \$10,750,013 USD
 Total Remaining to be Sold \$0 USD or Indefinite

Clarification of Response (if Necessary):

This amount includes proceeds from the sale of common shares pursuant to a separate registered direct offering, as well as the warrants covered by this filing. The amount does not include proceeds from the exercise of warrants.

14. Investors

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering. Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as

14

accredited investors, enter the total number of investors who already have invested in the offering:

15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions	\$860,001 USD	Estimate
Finders' Fees	\$0 USD	Estimate

Clarification of Response (if Necessary):

H.C. Wainwright & Co., LLC also received warrants to purchase 233,442 warrants of common stock. The compensation also covers the sale of common stock in the concurrent registered direct offering, as well as the warrants covered by this filing.

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$0 USD Estimate

Clarification of Response (if Necessary):

Some of the proceeds may be used for working capital and other general corporate purposes, which may include the payment of salaries and other fees to those listed in item 3.

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
EYEGATE PHARMACEUTICALS INC	/s/ Sarah Romano	Sarah Romano	Chief Financial Officer	2021-08-23

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a

result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.
